<DOC>
	<DOCNO>NCT00497107</DOCNO>
	<brief_summary>The purpose study conduct randomise control trial ( RCT ) compare UFT/LV UFT/LV + PSK patient histological stage IIIa/IIIb colorectal cancer undergone curative surgery without residual cancer use 3-year disease free survival ( DFS ) primary endpoint , also analyze 3-year overall survival ( OS ) , compliance , adverse event , quality life ( QOL ) relationship tumor factor .</brief_summary>
	<brief_title>Uracil Tegafur/Leucovorin ( UFT/LV ) Versus UFT/LV+ Polysaccharide-K ( PSK ) Stage IIIa/IIIb Colorectal Cancer</brief_title>
	<detailed_description>To conduct randomize controlled trial compare chemotherapy use UFT/LV immunochemotherapy use UFT/LV combine PSK patient histological stage IIIa IIIb colorectal cancer ( adenocarcinoma ) undergone curative surgery without residual cancer ( R0 ) use 3-year disease-free survival rate primary endpoint , also analyze 3-year overall survival , compliance , adverse event , QOL relationship tumor factor .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patient histological diagnosis primary colon rectal cancer ( adenocarcinoma ) Patient histological stage IIIa IIIb cancer ( accord Japanese Classification Colorectal Cancer , 7th edition ) Patient undergone curative surgery residual cancer Pretreatment criterion : patient undergone preoperative cancer treatment ( radiotherapy , chemotherapy immunotherapy ) Patient least 20 year 80 year age Patient performance status ( PS ) 01 ( accord Eastern Cooperative Oncology Group , ECOG ) Restrictions concomitant medication therapy : except case metastasis recurrence , concomitant use chemotherapeutic immunotherapeutic agent may affect result trial , concomitant use radiotherapy prohibit principle . Organ function ( laboratory data ) : patient satisfies follow condition data laboratory test conduct within 2 week prior start trial Gastrointestinal function : diarrhea ( watery stool ) White blood cell count : &gt; 4,000/mm3 Platelet count : &gt; 100,000/mm3 Serum GOT GPT : &lt; 100 IU/L Serum total bilirubin : &lt; 2.0 mg/dL Serum creatinine : upper limit facility normal range Patient residual cancer ( R1 R2 ) Patient anal canal lesion ( P ) perianal skin lesion ( E ) Patient stricture capable oral intake Patient pass fresh blood gastrointestinal tract Patient retention body cavity fluid necessitate treatment Patient infection , intestinal palsy intestinal occlusion Patient active multiple cancer patient less 5 year remission metachronous cancer ( except carcinoma situ skin cancer ) Patient pregnant wish become pregnant trial Patient continuous insulin treatment diabetes poorly control diabetes Patient history ischemic heart disease judge difficulty participate trial Patient concurrent psychiatric disease neurological symptom judge difficulty participate trial Patient continuous steroid therapy Patient history serious drug allergy Patient judge reason investigator doctor charge inappropriate subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>UFT/LV</keyword>
	<keyword>PSK</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Adjuvant therapy</keyword>
</DOC>